Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) was the target of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 3,991,736 shares, a decrease of 32.5% from the December 31st total of 5,910,789 shares. Currently, 7.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,084,209 shares, the short-interest ratio is presently 3.7 days. Based on an average daily trading volume, of 1,084,209 shares, the short-interest ratio is presently 3.7 days. Currently, 7.3% of the shares of the stock are short sold.

Zevra Therapeutics Stock Up 1.6%

ZVRA opened at $9.00 on Friday. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The business has a 50 day moving average price of $8.64 and a two-hundred day moving average price of $9.50. The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46. The company has a market cap of $506.68 million, a PE ratio of 19.15 and a beta of 1.08.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The business had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. As a group, research analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently modified their holdings of ZVRA. Ameritas Investment Partners Inc. raised its position in Zevra Therapeutics by 30.0% during the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after acquiring an additional 1,280 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Zevra Therapeutics by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock worth $179,000 after purchasing an additional 1,750 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after buying an additional 1,812 shares in the last quarter. CWM LLC lifted its stake in Zevra Therapeutics by 399.5% in the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after buying an additional 2,297 shares in the last quarter. Finally, Carret Asset Management LLC grew its holdings in Zevra Therapeutics by 9.7% during the 2nd quarter. Carret Asset Management LLC now owns 39,640 shares of the company’s stock valued at $349,000 after buying an additional 3,500 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZVRA. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Cantor Fitzgerald cut their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Friday, January 9th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zevra Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.80.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.